Health
Viking Therapeutics starts VK2735 maintenance trial
Viking Therapeutics (NASDAQ:VKTX) initiated an exploratory trial evaluating oral and dosing maintenance options for its lead obesity candidate, VK2735.
United States Health
Health
Kamada expands biosimilar portfolio with new launches
Kamada (NASDAQ:KMDA) expanded its commercial biosimilar portfolio in Israel with the market launch of Ustekinumab-Kamada and Enoxaparin-Kamada.
Health
BD partners with US on $19 billion manufacturing investment
BD (NYSE:BDX) partnered with the U.S. government to expand domestic manufacturing and supply chain infrastructure for critical medical consumables.
Health
Crescent receives FDA clearance for CR-002 trial
Crescent Biopharma (NASDAQ:CBIO) received FDA clearance for its Investigational New Drug application for CR-002, an antibody-drug conjugate being developed for advanced solid tumors.
Health
Alterity Therapeutics presents Phase 2 ATH434 MSA data
Alterity Therapeutics (NASDAQ:ATHE) reported additional Phase 2 analyses showing ATH434 50 mg slowed functional decline in multiple system atrophy by approximately 52% compared with placebo at Week 52.
Health
Abbott wins FDA approval for CardioMEMS HF smartphone app updates
Abbott (NYSE:ABT) received regulatory clearance from the U.S. Food and Drug Administration for major software capabilities connected to its implanted heart-monitoring platform.
Health
Establishment Labs secures FDA approval for expanded Motiva implants
Establishment Labs Holdings (NASDAQ:ESTA) secured U.S. Food and Drug Administration approval for an expanded range of Motiva SmoothSilk Round and Ergonomix breast implants.
Health
GE HealthCare acquires SOFIE Biosciences for $945 million
GE HealthCare (NASDAQ:GEHC) executed a definitive agreement to acquire SOFIE Biosciences from Trilantic North America for a cash purchase price of $945 million.
Health
Alector inks global licensing agreement with Genentech for AL050
Alector (NASDAQ:ALEC) executed an exclusive global licensing agreement with Genentech for AL050, an investigational enzyme replacement therapy targeting Parkinson’s disease.
Health
Harrow closes acquisition of TYRVAYA from Viatris
Harrow (NASDAQ:HROW) closed the acquisition of TYRVAYA from Viatris to expand its commercial ophthalmic portfolio with an approved dry eye treatment.
Health
Rezolute receives FDA guidance for ersodetug pre-BLA meeting
Rezolute (NASDAQ:RZLT) announced that the U.S. Food and Drug Administration recommended a pre-BLA meeting prior to any potential biologics license application for ersodetug.
Health
Stoke Therapeutics reviews 5-year data at FDA meeting
Stoke Therapeutics (NASDAQ:STOK) announced the successful completion of a meeting with the U.S. Food and Drug Administration regarding its investigational zorevunersen treatment.